Skip to content

CALIBER Phase 1: A Pilot Study in Normal-weight and Overweight Adults.

CALIBER (Carbohydrates, Lipids and Biomarkers of Traditional and Emerging Cardiometabolic Risk Factors) Phase 1: A Pilot Study in Normal-weight and Overweight Adults.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03257085
Acronym
CALIBER
Enrollment
15
Registered
2017-08-22
Start date
2017-03-09
Completion date
2017-12-08
Last updated
2018-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiometabolic Risk

Brief summary

Pilot study to compare the impact of following a low-carbohydrate, high-fat diet versus following a high-carbohydrates, moderate-fat diet (UK dietary guidelines) on cardiometabolic risk markers and associated behaviours in a normal-weight and overweight adult population.

Detailed description

Cardiometabolic diseases (CMD), such as type 2 diabetes and cardiovascular disease (CVD), are globally amongst the highest contributors to morbidity and mortality with high (cost) implications to the overall economy and health care systems. A number of risk markers have been associated with CMDs, including blood serum markers, low levels of lean mass and high levels of body fat, including increased waist circumference. Dietary factors and nutritional status have long been linked with specific markers of cardiometabolic (CM) risk. The quantity and quality of dietary carbohydrates has been associated with increased serum triglycerides levels, increased body fat mass, increased waist circumference and visceral fat around the organs in particular. They also seem to increase food cravings. Whilst official dietary guidelines in the UK and elsewhere still recommend a high carbohydrate and low fat diet as standard, these recommendations have increasingly been challenged. Evidence has been mounting that very-low carbohydrate (ketogenic) and low carbohydrate diets can ameliorate CM risk factors, especially when a personalised rather than a one-size-fits-all approach is being taken. Response to carbohydrate load and adherence to dietary interventions can vary widely dependent on individual substrate and energy metabolism and insulin-resistant status. The majority of dietary interventions with ketogenic and low-carbohydrate diets has focused on weight loss as the primary outcome in overweight and obese individuals. However, in recent years evidence has been mounting that the location and quality of adipose tissue (AT) play a more important role in manifestation of CM risk than quantity of AT alone. Detrimental health behaviours, such as low-quality diet and low levels of physical activity seem to be important contributors to this. Further studies can provide vital insights into the links between diet, location-specific adipose tissue, CM risk factors and health-related behaviours. Therefore this 8-weeks randomised pilot study will investigate the impact of either following a low-carbohydrate, high-fat diet versus following a high-carbohydrates, moderate-fat diet (UK dietary guidelines) on cardiometabolic risk markers and associated behaviours in a normal-weight and overweight adult population aged 19 - 64 at potential risk of CMD.

Interventions

OTHERLow-carbohydrate, high-fat

Participants following low-carbohydrate, high-fat diet for 8 weeks.

OTHERHigh-carbohydrate, moderate-fat

Participants following high-carbohydrate, moderate-fat diet (UK dietary guidelines) for 8 weeks.

Sponsors

Liverpool Hope University
CollaboratorOTHER
Liverpool John Moores University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Masking description

Due to the nature of the low-carbohydrate, high-fat and high-carbohydrate, moderate-fat diets masking is not feasible.

Intervention model description

Randomised pilot study

Eligibility

Sex/Gender
ALL
Age
19 Years to 64 Years
Healthy volunteers
Yes

Inclusion criteria

cohort 1: 1. BMI 18.5 - 29.9kg/m2 2. Aged 19 - 64 3. White-Caucasian 4. Score of ≥4 from a combination of risk markers, including * Fasting glucose concentration \>5.5mmol/L = 3 points * Waist \>102cm or 40 inches = 2 points (males) * Waist \>94 cm or 37 inches = 1 point (males) * Waist \>88cm or 34inches = 2 points (females) * Waist \>80 cm or 31 inches = 1 point (females) * Systolic blood pressure\>130mmHg = 1 point * Diastolic BP \>85mmHg = 1 point * HDL cholesterol concentration \<1.0mmol/L = 2 points * Serum triglyceride concentration \>1.3mmol/L = 1 point.

Exclusion criteria

cohort 1: 1. Smoker 2. Vegetarian or vegan 3. Suffering from food allergies or intolerances 4. Drinking alcohol above recommended UK government guidelines 5. Previous diagnosis of CM disease 6. Taking lipid-lowering medication 7. Taking blood pressure-lowering medication 8. Taking blood glucose-lowering medication 9. Taking dietary supplements 10. Suffering from an eating disorder 11. Current or previous renal impairment Inclusion Criteria cohort 2: 1. BMI 18.5 - 29.9kg/m2 2. Aged 19 - 64 3. White-Caucasian

Design outcomes

Primary

MeasureTime frameDescription
Serum lipid profile8 weeksTotal cholesterol, HDL-C, LDL-C, non-HDL cholesterol, small-dense LDL-C and triglycerides measured in mmol/L
Blood glucose8 weeksMeasured in mmol/L
Systolic and diastolic blood pressure8 weeksMeasured in mmHg
Inflammatory markers, such as CRP8 weeksMeasured in mg/L
Adiponectin8 weeksMeasured in μg/mL
Fibroblast growth factor 21 (FGF21).8 weeksMeasured in pg/mL
Tumor necrosis factor alpha and Interleukin 68 weeksMeasured in μg/mL
Body composition - Bioelectrical impedance8 weeksLean mass, fat mass and adipose tissue location and distribution
Body composition - Anthropometrics8 weeksWaist, hip, neck, thigh and calf circumference measured in cm

Secondary

MeasureTime frameDescription
Adherence to taking dietary supplement for low-carbohydrate, high-fat group8 weeksMeasured via counting of number of multi-vitamin and mineral supplements consumed
Clinical traditional and emerging markers of dietary intake8 weeksFibroblast growth factor 21 and serum metabolites
Experience with either low-carbohydrate, high-fat or high-carbohydrate, moderate-fat diet8 weeksAssessed via semi-structured interview
Food cravings8 weeksMeasured via self-reported questionnaire
Satiety8 weeksAssessed via serum leptin levels (ng/mL)
Cognition8 weeksAssessed via self-reported questionnaire
Impact on physical activity patterns8 weeksAssessed via accelerometry
Adherence to assigned diet8 weeksMeasured via 4-day food diaries
Adherence to dietary guidelines8 weeksMeasured via diet quality score assessment
Adherence to low-carbohydrate diet8 weeksMeasured via blood ketones (mmol/L)
Adherence to fibre recommendations8 weeksMeasured via structured questionnaires

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026